Buck Wealth Strategies LLC Increases Stake in Amgen Inc. (NASDAQ:AMGN)

Buck Wealth Strategies LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 20.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 33,718 shares of the medical research company's stock after purchasing an additional 5,712 shares during the quarter. Amgen comprises about 1.9% of Buck Wealth Strategies LLC's holdings, making the stock its 17th biggest holding. Buck Wealth Strategies LLC's holdings in Amgen were worth $10,505,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Advisor Resource Council bought a new position in Amgen during the 1st quarter valued at about $1,331,000. Ascent Wealth Partners LLC lifted its stake in Amgen by 0.7% during the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock valued at $2,352,000 after acquiring an additional 64 shares during the period. Fisher Asset Management LLC lifted its stake in Amgen by 285.4% during the 4th quarter. Fisher Asset Management LLC now owns 394,489 shares of the medical research company's stock valued at $102,820,000 after acquiring an additional 292,137 shares during the period. Aire Advisors LLC lifted its stake in Amgen by 26.3% during the 4th quarter. Aire Advisors LLC now owns 13,280 shares of the medical research company's stock valued at $3,461,000 after acquiring an additional 2,762 shares during the period. Finally, Beacon Harbor Wealth Advisors Inc. bought a new position in Amgen during the 4th quarter valued at about $3,531,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

Amgen stock traded down $0.30 during midday trading on Friday, hitting $289.33. The stock had a trading volume of 6,801,322 shares, compared to its average volume of 2,818,791. The firm's fifty day moving average is $281.82 and its two-hundred day moving average is $286.10. The company has a market capitalization of $155.58 billion, a PE ratio of 26.40, a P/E/G ratio of 2.62 and a beta of 0.51. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.96 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company's stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.69% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research analyst reports. UBS Group restated a "neutral" rating and set a $315.00 target price (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Piper Sandler reduced their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Royal Bank Of Canada reduced their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Bank of America upped their price target on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Finally, Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.